Abstract
Mergers and acquisitions in the pharmaceutical industry have substantially reduced the number of major companies over the past 15 years. The short-term business rationale for this extensive consolidation might have been reasonable, but at what cost to research and development productivity?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Innovation crisis in the pharmaceutical industry? A survey
SN Business & Economics Open Access 11 November 2021
-
Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact
Pharmaceutical Research Open Access 06 June 2017
-
Plate-based diversity subset screening generation 2: an improved paradigm for high-throughput screening of large compound files
Molecular Diversity Open Access 08 September 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Rev. Drug Discov. 9, 203–214 (2010).
Garnier, J.-P. Rebuilding the R&D engine in Big Pharma. Harvard Bus. Rev. 86, 68–76 (2008).
Munos, B. Lessons from 60 years of pharmaceutical innovation. Nature Rev. Drug Discov. 8, 959–968 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Supplementary information
Supplementary information S1 (figure)
Approvals of new chemical entities by the US FDA: 1940–2010 (PDF 303 kb)
Rights and permissions
About this article
Cite this article
LaMattina, J. The impact of mergers on pharmaceutical R&D. Nat Rev Drug Discov 10, 559–560 (2011). https://doi.org/10.1038/nrd3514
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3514
This article is cited by
-
Many are called, few are chosen: the role of science in drug development decisions
The Journal of Technology Transfer (2023)
-
Innovation crisis in the pharmaceutical industry? A survey
SN Business & Economics (2021)
-
Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact
Pharmaceutical Research (2017)
-
Changing R&D models in research-based pharmaceutical companies
Journal of Translational Medicine (2016)
-
Plate-based diversity subset screening generation 2: an improved paradigm for high-throughput screening of large compound files
Molecular Diversity (2016)